CADL
NASDAQCandel Therapeutics Inc.
Website
News25/Ratings12
News · 26 weeks37-37%
2025-10-262026-04-19
Mix2990d
- Insider9(31%)
- Other9(31%)
- SEC Filings7(24%)
- Offering3(10%)
- Analyst1(3%)
Latest news
25 items- ANALYSTCantor Fitzgerald initiated coverage on Candel TherapeuticsCantor Fitzgerald initiated coverage of Candel Therapeutics with a rating of Overweight
- INSIDERSEC Form 4 filed by Manning Paul B4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Papa Joseph C4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Loggia Nicoletta4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on March 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to five new employees, stock options to purchase an aggregate of 70,000 shares of the Company's common stock, with a per share exercise price of $4.90. The inducement stock options were made under the Company's 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award o
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Candel Therapeutics Inc.SCHEDULE 13D/A - Candel Therapeutics, Inc. (0001841387) (Subject)
- PRCandel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint InhibitorsExtended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene besadenovec (aglatimagene or CAN-2409) surviving beyond 24 months, despite prior inadequate response to immune checkpoint inhibitors (ICI) and multiple adverse baseline prognostic factors.Among the patients surviving beyond 24 months and with PD-L1 status available, (17/20) 85% had baseline PD-L1 tumor proportion scores (TPS) below 50% (a population typically less responsive to ICI), supporting the potential of aglatimagene to upregulate PD-L1 in the tumor microenvironment and convert
- SECSEC Form S-8 filed by Candel Therapeutics Inc.S-8 - Candel Therapeutics, Inc. (0001841387) (Filer)
- SECSEC Form 10-K filed by Candel Therapeutics Inc.10-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- SECCandel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsCompany plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026Company plans to submit a Biologics License Application (BLA) for aglatimagene in localized, intermediate-to high-risk prostate cancer in Q4 2026Company announced investigational new drug (IND) clearance for linoserpaturev (CAN-3110) in recurrent high-grade glioma (rHGG) to support enabling work for a potential future randomized controlled phase 2 dose regimen finding study.Entered into a $130 million term loan facility with Tri
- PRCandel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual MeetingNEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for oral presentation in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session, as part of the American Urological Association (AUA) 2026 Annual Meeting Plenary Program being held in Washington D.C. from May 15-18, 2026. The presentation will feature new data from the Company's phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with interm
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on February 28, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 20,000 shares of the Company's common stock, with a per share exercise price of $5.25. The inducement stock options were made under the Company's 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award
- INSIDERDirector Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- PRCandel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in BostonNEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at TD Cowen's 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday, March 3, 2026 Time: 11:50 AM - 12:20 PM ET Webcast Link: TD Cowen / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News &
- SECSEC Form 8-K filed by Candel Therapeutics Inc.8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- SECSEC Form 424B5 filed by Candel Therapeutics Inc.424B5 - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Announces Pricing of Public OfferingNEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 18,348,624 shares of its common stock at a price to the public of $5.45 per share. The gross proceeds to Candel from the offering are expected to be $100 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about February 23, 2026, subject to customary closing conditions. In addition, Candel has grant
- SECSEC Form 424B5 filed by Candel Therapeutics Inc.424B5 - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Announces Proposed $100 Million Public OfferingNEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten public offering of $100 million of its common stock. Candel also intends to grant the underwriters a 30-day option to purchase up to an additional $15 million in shares of its common stock on the same terms and conditions. All shares of common stock to be sold in the offering will be offered by Candel. The offering is subject to market conditions, and there can be no assurance as to whether or when t
- SECCandel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate CancerRTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized prostate cancer Royalties based on annual net sales of aglatimagene in the U.S.Funds will strengthen the Company's balance sheet for potential U.S. commercial launch of aglatimagene in intermediate- to high-risk localized prostate cancer NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight
- PRCandel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development SummitNEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Francesca Barone, M.D., Ph.D., Candel's Chief Scientific Officer, will present data and participate in multiple sessions at the 7th Annual Glioblastoma Drug Development Summit, taking place February 17-19, 2026 in Boston, Massachusetts. Dr. Barone will share insights from Candel's HSV-based platform and the linoserpaturev (CAN-3110) program in recurrent high-grade glioma (rHGG) through workshop presentations and panel discu
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on January 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 6,600 shares of the Company's common stock, with a per share exercise price of $5.84. The inducement stock options were made under the Company's 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award on
- INSIDERSEC Form 4 filed by Chief Technology Officer Tyagarajan Seshu4 - Candel Therapeutics, Inc. (0001841387) (Issuer)